Genelux GmbH
Genelux is a Phase 3 biopharmaceutical company dedicated to developing powerful therapeutics with the potential to redefine immuno-oncology across multiple indications. The company focuses on next-generation immunotherapies, including oncolytic virotherapies, to treat aggressive and difficult-to-treat solid tumors. Their mission is to deliver personalized immune responses to fight cancer, individual by individual, leveraging their proprietary CHOICE™ discovery platform. They aim to support their clinical development through collaborations, support a broad pipeline including Olvi-Vec, and have a strategic focus on addressing unmet medical needs in oncology. Additionally, Genelux is committed to developing safe and effective next-generation immunotherapies and may provide expanded access to investigational therapies under limited situations for patients with serious or life-threatening conditions when clinical trials are not suitable.
Industries
Nr. of Employees
small (1-50)
Patents
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US-10584317-B2
View DetailsOncolytic virus adjunct therapy with agents that increase virus infectivity
US-10238700-B2
View DetailsModified vaccinia virus strains for use in diagnostic and therapeutic methods
US-9944903-B2
View Details
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US-10584317-B2
View DetailsOncolytic virus adjunct therapy with agents that increase virus infectivity
US-10238700-B2
View DetailsModified vaccinia virus strains for use in diagnostic and therapeutic methods
US-9944903-B2
View DetailsProducts
Oncolytic vaccinia-based clinical candidate (lead clinical candidate for platinum-resistant ovarian cancer)
An investigational oncolytic vaccinia virus therapeutic developed for regional intraperitoneal administration in platinum-resistant/refractory ovarian cancer and studied systemically in other solid tumors; evaluated as monotherapy and in combination with chemotherapy and other modalities.
Oncolytic vaccinia discovery library and engineered strain portfolio
A library of engineered vaccinia virus strains and transgene-armed constructs intended as a discovery engine for multiple therapeutic candidates across tumor types.
Veterinary oncolytic vaccinia candidate (licensed veterinary product)
A vaccinia viral strain developed for oncology in non-human animals; out-licensed to a veterinary biotechnology company and evaluated in canine studies.
Oncolytic vaccinia-based clinical candidate (lead clinical candidate for platinum-resistant ovarian cancer)
An investigational oncolytic vaccinia virus therapeutic developed for regional intraperitoneal administration in platinum-resistant/refractory ovarian cancer and studied systemically in other solid tumors; evaluated as monotherapy and in combination with chemotherapy and other modalities.
Oncolytic vaccinia discovery library and engineered strain portfolio
A library of engineered vaccinia virus strains and transgene-armed constructs intended as a discovery engine for multiple therapeutic candidates across tumor types.
Veterinary oncolytic vaccinia candidate (licensed veterinary product)
A vaccinia viral strain developed for oncology in non-human animals; out-licensed to a veterinary biotechnology company and evaluated in canine studies.
Services
On-site cGMP production and scale-up of viral therapeutic material for clinical development using a proprietary large-scale manufacturing process.
Partnership-driven development, licensing and joint-venture arrangements to advance clinical programs and regional commercialization of viral therapeutics.
Case-by-case evaluation of physician-initiated expanded access requests for investigational therapies, including eligibility assessment, safety and trial-interference review, supply verification, and confirmation of treating-physician regulatory/ethics approvals and storage/handling capability.
On-site cGMP production and scale-up of viral therapeutic material for clinical development using a proprietary large-scale manufacturing process.
Partnership-driven development, licensing and joint-venture arrangements to advance clinical programs and regional commercialization of viral therapeutics.
Case-by-case evaluation of physician-initiated expanded access requests for investigational therapies, including eligibility assessment, safety and trial-interference review, supply verification, and confirmation of treating-physician regulatory/ethics approvals and storage/handling capability.
Expertise Areas
- Oncolytic virotherapy development
- Clinical trial management (Phase 1–3, registrational trials)
- Viral vector engineering and transgene design
- GMP biologics manufacturing and scale-up
Key Technologies
- Vaccinia-based oncolytic virus platforms
- Viral vector genetic engineering
- Transgene payload engineering
- Regional intraperitoneal delivery methods
News & Updates
A clinical publication detailing a phase III study of Olvi-Vec in ovarian cancer, demonstrating efficacy and safety.
A study showing the clinical activity of Olvi-Vec in heavily pretreated ovarian cancer patients, indicating promising efficacy.
An editorial discussing the potential of vaccinia virus in ovarian cancer treatment.
A phase I trial analyzing the immune response and oncolytic activity of Olvi-Vec in mesothelioma.
A phase 3 clinical trial evaluating Olvi-Vec in ovarian cancer, with topline results expected in 2H 2025.
A clinical publication detailing a phase III study of Olvi-Vec in ovarian cancer, demonstrating efficacy and safety.
A study showing the clinical activity of Olvi-Vec in heavily pretreated ovarian cancer patients, indicating promising efficacy.
An editorial discussing the potential of vaccinia virus in ovarian cancer treatment.
A phase I trial analyzing the immune response and oncolytic activity of Olvi-Vec in mesothelioma.
A phase 3 clinical trial evaluating Olvi-Vec in ovarian cancer, with topline results expected in 2H 2025.